Hi 

More Sensational Breaking News!

MindBio Therapeutics is pleased to announce that ethics approval has been received for a world’s first Phase 2a take-home LSD-Microdosing clinical trial in patients with Major Depressive Disorder.  

The trial has also been approved by the Clinical Trials Registry.

Major depressive disorder (MDD) is the leading cause of global disability, with over 260 million people affected.

In this open-label trial in 20 patients with major depressive disorder (MDD) the tolerability and feasibility of an 8-week regimen of LSD-Microdosing will be tested.  

The results will inform a continuation trial, a much larger Phase 2b randomized triple-dummy active placebo-controlled trial in patients with Major Depressive Disorder.

In 2022, MindBio’s Phase 1 take-home LSD-Microdosing clinical trial in 80 healthy participants yielded positive topline results.  The randomized, double-blind and placebo-controlled clinical trial found on dose days, participants in the LSD-Microdosing group experienced increases in:

1.     Happiness

2.     Social connectivity

3.     Creativity

4.     Wellness

5.     Energy

We are pleased to be advancing our microdosing treatments to Phase 2 clinical trials.  

Psychedelic microdosing proposes to be a globally scalable solution to treating mental health conditions and we are excited by the data we are seeing and the potential future commercialization opportunities for these medicines.

We invite you to join us in support of creating a brighter future for mental health.

Stay well!

Justin Hanka 

Cofounder and Chief Executive

Receive our latest updates here:

 https://www.mindbiotherapeutics.com/get-updates

Follow MindBio on LinkedIn:

 https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true

Follow CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/